Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Effects of Repeated Psilocybin Dosing in OCD
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 30
- Registration Number
- NCT05370911
- Locations
- πΊπΈ
Connecticut Mental Health Center, New Haven, Connecticut, United States
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 12
- Registration Number
- NCT05322954
- Locations
- πΊπΈ
University of Wisconsin, Madison, Wisconsin, United States
Comparing the Effects of Psilocin and Psilocybin in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 20
- Registration Number
- NCT05317689
- Locations
- πΊπΈ
University of California, San Francisco, San Francisco, California, United States
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 22
- Registration Number
- NCT05312151
- Locations
- πΊπΈ
Sunstone Therapies, Rockville, Maryland, United States
πΊπΈIcahn School of Medicine at Mount Sinai, New York, New York, United States
π¬π§Kings College London, Institute of Psychiatry, Psychology and Neurology, London, United Kingdom
Effects of Psilocybin in Post-Treatment Lyme Disease
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 20
- Registration Number
- NCT05305105
- Locations
- πΊπΈ
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 30
- Registration Number
- NCT05301608
- Locations
- πΊπΈ
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- University of California, Berkeley
- Target Recruit Count
- 80
- Registration Number
- NCT05265546
- Locations
- πΊπΈ
University of California, Berkeley, Berkeley, California, United States
Mood and Cognitive Effects of Psilocybin in Healthy Participants
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Optimi Health Corporation
- Registration Number
- NCT05252598
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Halucenex Life Sciences Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05243329
- Locations
- π¨π¦
Halucenex Life Sciences Inc., Windsor, Nova Scotia, Canada
Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT05242029
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.